Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum-Resistant Ovarian Cancer

July 27, 2023 9:00 am

The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.

 

The phase 1/2 UPLIFT trial (NCT03319628) … Read more

DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors

June 7, 2023 6:55 am

Key Points:

  • Interim results of the phase 2 trial DESTINY-PanTumor-02 show that T-DXd has broad activity across tumor types and a toxicity profile consistent with previous studies.
  • T-DXd had the lowest activity in pancreatic cancer, and this cohort was stopped
Read more

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

June 4, 2023 6:58 am

Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the … Read more

Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer

June 3, 2023 7:02 am

Key takeaways:

  • Researchers reported statistically significant improvement in median PFS with the combination added to standard of care in non-BRCA-mutated disease.
  • The relative contribution of durvalumab requires further study.

 

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more

Mirvetuximab Soravtansine Continues to Outperform Chemo in FRα-High Ovarian Cancer

May 3, 2023 9:19 am

by Jordan Sava

Impressive efficacy data and consistent safety data continue to be seen with mirvetuximab soravtansine for the treatment of patients with platinum-resistant ovarian cancer, according to data from the confirmatory MIRASOL trial.

Mirvetuximab sorvtansine-gynx (Elahere) demonstrated statistically significant

Read more

Dual Inhibition of PARP and ATR Feasible, Early Trials Suggest

April 19, 2023 12:40 pm

by Leah Lawrence

Early-phase trials testing the safety and efficacy of PARP inhibition plus ataxia telangiectasia- and Rad3-related kinase (ATR) inhibition in biomarker-selected patients show intriguing results, researchers reported at the AACR Annual Meeting 2023.

“ATR inhibition prevents recovery from … Read more

SWOG investigators report results from DART clinical trial of immunotherapy combination for rare gynecologic cancers

April 18, 2023 10:20 am

Reviewed by Emily Henderson, B.Sc

Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare … Read more

Lifirafenib Plus Mirdametinib Shows Tolerable Safety in BRAF/KRAS Mutant Advanced Solid Tumors

April 17, 2023 12:29 pm

by Nichole Tucker

The success of BRAF/MEK combinations has led to the discovery of safety and preliminary activity with an investigational pan-RAF/MEK combination.

The investigational combination of lifirafenib (BGB-283) and mirdametinib (PD-0325901) has shown a favorable safety profile, as well Read more

Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations

April 5, 2023 4:55 pm

by Nichole Tucker

The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting Read more

CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer

March 27, 2023 9:52 am

by Charles Bankhead

TAMPA, Fla. — About a fourth of patients with recurrent low-grade serous ovarian cancer (LGSOC) obtained durable responses to the combination of CDK4/6 inhibitor ribociclib (Kisqali) and letrozole, a small single-arm trial showed.

Overall, 23% of 48 … Read more

Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer

March 27, 2023 9:13 am

by Devin McLaughlin

Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Researchers observed favorable surgical outcomes — even … Read more

Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer

March 27, 2023 9:11 am

by Jason Harris

Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1Read more

Tailored Phone Calls Increased Rate of Genetic Testing, Counseling for Hereditary Cancer Risk

March 2, 2023 9:44 am

by Alison Kanski

NEW YORK – Personalized phone discussions about genetic risk assessment increased the number of breast and ovarian cancer patients who got genetic testing or discussed their risk with a genetic counselor, a study from Rutgers Cancer Institute … Read more

Avutometinib Plus Defactinib Generates Encouraging Response Rates in LGSOC

January 26, 2023 1:00 pm

by Jordyn Sava

With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.

The combination of avutometinib (VS-6766) with defactinib (VS-6063), as … Read more

Acupuncture, acupressure may benefit women undergoing gynecologic cancer surgery

January 17, 2023 10:20 am

by Jennifer Southall

Women who underwent surgery for gynecologic cancers experienced decreased symptoms of anxiety and pain with the use of acupressure before surgery and acupuncture during surgery, according to study results published in Cancer.

Further investigation is needed … Read more

Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer

January 16, 2023 10:07 am

by Caroline Seymour

Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.

Treatment with the folate receptor

Read more

Targeting FRα Enters a New Era in Ovarian Cancer and Beyond

January 16, 2023 9:41 am

by Anita T. Shaffer

Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.Read more

COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer

January 12, 2023 10:08 am

by Ryan Scott

A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.

A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo)

Read more

Yale Cancer Center Research Helps Expand NCCN Guidelines for Ovarian Cancer

January 5, 2023 10:50 am

by Eliza Folsom

Results from a recent Yale Cancer Center Phase II trial studying ixabepilone and bevacizumab vs ixabepilone alone in platinum resistant ovarian cancer patients have led to the combination added as a Category 2B recommended regimen in Ovarian … Read more

Racial, ethnic minority groups lack representation in OB/GYN trials

January 4, 2023 10:23 am

by Kalie VanDewater

Reporting of race and ethnicity data and representation of different racial and ethnic populations in OB/GYN clinical trials are subpar, although improvement is possible, according to findings published in JAMA Surgery.

“Although trial results inform policies … Read more